En esta página
01CYTK precio
02Instantánea
03Gráfico
04Divisiones de acciones
05Acerca de
06Rendimiento
07Valoración y ratios
14Ganancias
15Fundamentales Completos
16Estados Financieros
17Propietarios institucionales (13F)
19Informantes de la empresa
20Propiedad de ETFs
21Consenso
22Pares
23Noticias
26Mis Métricas
CYTK Cytokinetics, Incorporated - Common Stock
NASDAQ · Biotechnology · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 6, 2026
$65,60
· % del rango de 52 semanas
· por encima del mínimo
· a alto
$54,30mínimo 52 semanas
$88,31máximo 52 semanas
Capitalización Bursátil
$8.07B
P/E (TTM)
-9.1
BPA (TTM)
$-7.23
Ingresos (TTM)
$68M
tus insignias
Rango 52S
$54–$88
Calificación del Analista
BUY
Precio Objetivo
$110
P/E
-9.1
ROE
329.8%
Margen de Beneficio Neto
-1321.1%
Tu barra de insignias está vacía — fija una métrica en cualquier lugar de esta página.
CYTK Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$65.60
Capitalización Bursátil
$8.07B
P/E (TTM)
-9.1
BPA (TTM)
$-7.23
Ingresos (TTM)
$68M
ROE (TTM)
329.8%
Deuda/Capital (MRQ)
-1.6
Rango 52S
$54–$88
CYTK Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
rango
barras
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Divisiones de acciones
| Fecha ex-dividendo | División | Tipo |
|---|---|---|
| 25 de junio de 2013 | 1-for-6 | Inversa |
Acerca de Cytokinetics, Incorporated - Common Stock Descripción general de la empresa de Wikipedia
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
sectorHealthcare
industriaBiotechnology
empleados673
paísUS
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos$88M2016-12-31 → 2025-12-31
BPA$-6.542016-12-31 → 2025-12-31
Flujo de caja libre$-535M2016-12-31 → 2025-12-31
Margen neto-1321.1%2016-12-31 → 2025-12-31
Valoración y ratios
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | CYTK | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E (TTM) | -9.1promedio 5A ≈-12.2 | ≈-12.2 | · | · | |
| P/S | 91.6promedio 5A ≈323.5 | ≈323.5 | 41.9 | Sobrevalorado | |
| P/B (P/C) | -12.2promedio 5A ≈-19.9 | ≈-19.9 | · | · | |
| EV / EBITDA | -13.7promedio 5A ≈-15.1 | ≈-15.1 | · | · | |
| Price / FCF (Precio / FCF) | -15.1promedio 5A ≈-16.6 | ≈-16.6 | · | · | |
| Price / Cash Flow (Precio / Flujo de Caja) | -15.8promedio 5A ≈-18.3 | ≈-18.3 | · | · | |
| EV / Revenue (EV / Ingresos) | 93.5promedio 5A ≈322.6 | ≈322.6 | · | · | |
| EV / FCF | -15.4promedio 5A ≈-16.6 | ≈-16.6 | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | CYTK | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Margen Operativo (TTM) | -1046.1%promedio 5A ≈-2159.0% | ≈-2159.0% | -118.4% | Débil | |
| Margen EBITDA (TTM) | -1027.6%promedio 5A ≈-2113.0% | ≈-2113.0% | -118.4% | Débil | |
| Margen de Beneficio Neto (TTM) | -1321.1%promedio 5A ≈-2357.7% | ≈-2357.7% | -176.2% | Débil | |
| ROA (TTM) | -56.8%promedio 5A ≈-47.8% | ≈-47.8% | -22.9% | Débil | |
| ROE (TTM) | 329.8%promedio 5A ≈322.1% | ≈322.1% | -13.2% | De primer nivel |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | CYTK | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Deuda / Patrimonio (MRQ) | -1.6promedio 5A ≈-0.4 | ≈-0.4 | 0.3 | Baja deuda | |
| Ratio corriente (MRQ) | 6.7promedio 5A ≈6.7 | ≈6.7 | 5.9 | En línea | |
| Quick Ratio (Ratio Rápido) | 0.7promedio 5A ≈1.1 | ≈1.1 | 3.6 | Baja liquidez | |
| Deuda a Largo Plazo / Patrimonio (MRQ) | -1.4promedio 5A ≈-0.3 | ≈-0.3 | · | · | |
| Interest Coverage (Cobertura de Intereses) | -13.4promedio 5A ≈-14.6 | ≈-14.6 | -7.7 | Baja liquidez |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
| Métrica | Tendencia a 5 años | CYTK | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue YoY (Ingresos interanuales) | 376.6%promedio 5A ≈98.1% | ≈98.1% | · | · | |
| Revenue CAGR 3Y (Ingresos CAGR 3A) | -2.4%promedio 5A ≈-29.0% | ≈-29.0% | · | · | |
| Revenue CAGR 5Y (Ingresos CAGR 5A) | 9.5% | · | · | · |
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | CYTK | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Asset Turnover (Rotación de Activos) | 0.1promedio 5A ≈0.1 | ≈0.1 | 0.2 | Débil | |
| Receivables Turnover (Rotación de Cuentas por Cobrar) | 5.1promedio 5A ≈4.8 | ≈4.8 | 5.7 | En línea | |
| Revenue / Employee (Ingresos / Empleado) | ≈$130.8K | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
-4.4%
Próximo informe
Nov 03, 2026
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 5, 2026 | $-1.50 | $-1.67 | 10.4% |
| 31 de marzo de 2026 | $-1.67 | $-1.69 | 0.94% | |
| 31 de diciembre de 2025 | $-1.50 | $-1.49 | -0.97% | |
| 30 de septiembre de 2025 | $-2.55 | $-1.61 | -58.2% | |
| 30 de junio de 2025 | $-1.12 | $-1.41 | 20.3% | |
| 31 de marzo de 2025 | $-1.39 | $-1.41 | 1.4% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-5.37 | $-1.15 | $-3.80 | $-1.14 | $2.88 | $1.60 | $-0.18 | $0.47 | $2.04 | $2.32 | $1.73 | $2.38 | |
| Revenue / Share | $733.03 | $164.98 | $78.01 | $1053.03 | · | · | · | · | $0.27 | $2.50 | · | · | |
| Cash Flow / Share | $-4246.43 | $-3535.39 | $-4292.54 | $-3334.44 | · | · | · | · | $-2.06 | $0.87 | · | · | |
| Cash / Share | $1.00 | $0.80 | $1.11 | $0.69 | $1.33 | $1.17 | $0.62 | $0.77 | $2.32 | $1.65 | $1.64 | $0.52 | |
| EPS (TTM) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 |
Tasas de Crecimiento
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | · | 119,982 | 119,457 | 118,496 | · | 117,685 | 109,240 | 101,924 | · | 96,071 | 95,755 | 95,164 | · | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | · | 119,982 | 119,457 | 118,496 | · | 117,685 | 109,240 | 101,924 | · | 96,071 | 95,755 | 95,164 | · | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
Eficiencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $216.71 | $157.01 | · | $16.14 | $558.94 | $13.33 | · | $3.93 | $2.28 | $8.19 | · | $3.93 | $9.05 | $48.47 | · | $26.82 | |
| Cash Flow / Share | · | $-1179.96 | · | · | · | $-1110.73 | · | · | · | $-1270.62 | · | · | · | $-1285.00 | · | · | |
| EPS (TTM) | $-7.23 | $-6.85 | · | $-6.29 | $-5.10 | $-5.29 | · | $-5.38 | $-5.37 | $-5.40 | · | $-5.60 | $-5.77 | $-4.66 | · | $-3.12 |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $68M | $106M | · | $87M | $86M | $19M | · | $3M | $3M | $4M | · | $8M | $10M | $98M | · | $148M | |
| Net Income TTM | $-894M | $-830M | · | $-752M | $-606M | $-615M | · | $-576M | $-545M | $-531M | · | $-527M | $-540M | $-431M | · | $-282M | |
| P/E | -11.8 | -9.6 | · | -8.7 | -6.5 | -7.6 | · | -9.8 | -10.1 | -13.0 | · | -5.3 | -5.7 | -7.6 | · | -15.5 | |
| Earnings Yield | -8.5% | -10.4% | · | -11.4% | -15.4% | -13.2% | · | -10.2% | -9.9% | -7.7% | · | -19.0% | -17.7% | -13.2% | · | -6.4% |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | $88M | $18M | $8M | $95M | $70M |
| Margen Operativo % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| Beneficio neto | $-785M | $-590M | $-526M | $-389M | $-215M |
| EPS Diluido | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Deuda / Patrimonio | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| Ratio corriente | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| Ratio Rápido | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | $-535M | $-400M | $-416M | $-311M | $-191M |
Propietarios institucionales (13F) 535 declarantes · $13.2B total · A fecha de 30 de septiembre de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Tenedores
535
Valor en tenencia
$13.2B
Nuevas posiciones
95
Posiciones cerradas
49
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 95 (-11 vs trimestre anterior) | 49 (-7 vs trimestre anterior) | 238 (+49 vs trimestre anterior) | 113 (-29 vs trimestre anterior) | +10.8M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $1 711 838 738 | 20 094 362 | 12,99% | Acciones |
| VANGUARD GROUP INC | $765 538 243 | 12 048 131 | 5,81% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $590 517 486 | 6 931 770 | 4,48% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571 778 157 | 6 711 799 | 4,34% | Acciones |
| STATE STREET CORP | $553 243 709 | 6 494 233 | 4,20% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $521 151 103 | 6 117 515 | 3,95% | Acciones |
| FMR LLC | $428 657 534 | 5 031 782 | 3,25% | Acciones |
| Avoro Capital Advisors LLC | $425 949 915 | 4 999 999 | 3,23% | Acciones |
| BANK OF AMERICA CORP /DE/ | $394 916 049 | 4 635 709 | 3,00% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $316 325 896 | 3 712 501 | 2,40% | Acciones |
| RTW INVESTMENTS, LP | $243 814 036 | 2 862 003 | 1,85% | Acciones |
| Polar Capital Holdings Plc | $191 988 358 | 2 253 649 | 1,46% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161 060 214 | 1 890 600 | 1,22% | Opción de compra |
| GOLDMAN SACHS GROUP INC | $150 069 725 | 1 761 588 | 1,14% | Acciones |
| Capital Research Global Investors | $143 683 584 | 1 686 625 | 1,09% | Acciones |
| NORTHERN TRUST CORP | $140 337 319 | 1 647 345 | 1,06% | Acciones |
| JPMORGAN CHASE & CO | $139 150 046 | 1 588 895 | 1,06% | Acciones |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136 597 224 | 1 603 442 | 1,04% | Acciones |
| Integral Health Asset Management, LLC | $136 304 000 | 1 600 000 | 1,03% | Acciones |
| Point72 Asset Management, L.P. | $135 257 185 | 1 587 712 | 1,03% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133 388 883 | 1 565 781 | 1,01% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131 998 327 | 1 549 458 | 1,00% | Acciones |
| ARMISTICE CAPITAL, LLC | $130 340 700 | 1 530 000 | 0,99% | Opción de compra |
| MORGAN STANLEY | $128 664 004 | 1 510 318 | 0,98% | Acciones |
| PRINCIPAL FINANCIAL GROUP INC | $111 740 656 | 1 311 664 | 0,85% | Acciones |
| Capital International Investors | $111 245 191 | 1 305 848 | 0,84% | Acciones |
| Invesco Ltd. | $105 237 167 | 1 235 323 | 0,80% | Acciones |
| ARMISTICE CAPITAL, LLC | $102 342 325 | 1 201 342 | 0,78% | Acciones |
| UBS Group AG | $99 781 940 | 1 171 287 | 0,76% | Acciones |
| Pictet Asset Management Holding SA | $99 038 455 | 1 160 463 | 0,75% | Acciones |
| Frazier Life Sciences Management, L.P. | $98 810 092 | 1 159 879 | 0,75% | Acciones |
| Bank of New York Mellon Corp | $98 027 901 | 1 150 697 | 0,74% | Acciones |
| Holocene Advisors, LP | $97 506 685 | 1 144 579 | 0,74% | Acciones |
| Woodline Partners LP | $93 769 315 | 1 100 708 | 0,71% | Acciones |
| D. E. Shaw & Co., Inc. | $89 287 894 | 1 048 103 | 0,68% | Acciones |
| NORGES BANK | $86 512 319 | 1 015 522 | 0,66% | Acciones |
| Royalty Pharma Sub-Manager, LLC | $83 519 594 | 980 392 | 0,63% | Acciones |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81 937 000 | 961 815 | 0,62% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $77 218 175 | 906 423 | 0,59% | Acciones |
| CITADEL ADVISORS LLC | $77 062 874 | 904 600 | 0,58% | Opción de compra |
| FRANKLIN RESOURCES INC | $75 911 721 | 891 087 | 0,58% | Acciones |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $70 521 134 | 827 810 | 0,53% | Acciones |
| Melqart Asset Management (UK) Ltd | $65 385 455 | 767 525 | 0,50% | Acciones |
| Siren, L.L.C. | $64 655 121 | 758 952 | 0,49% | Acciones |
| Fisher Asset Management, LLC | $63 355 547 | 743 697 | 0,48% | Acciones |
| Foresite Capital Management IV, LLC | $60 884 867 | 714 695 | 0,46% | Acciones |
| Balyasny Asset Management L.P. | $60 599 821 | 711 349 | 0,46% | Acciones |
| Deep Track Capital, LP | $59 633 000 | 700 000 | 0,45% | Acciones |
| JANE STREET GROUP, LLC | $59 633 000 | 700 000 | 0,45% | Opción de compra |
| BNP PARIBAS FINANCIAL MARKETS | $58 702 470 | 689 077 | 0,45% | Acciones |
Informantes de la empresa 52 insiders · 19 directivos · 23 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Robert I Blum | President & CEO | 28 de septiembre de 2026 M | 278 544 | 0 | 20 | $-17 291 957 |
| Sung Lee | EVP, Chief Financial Officer | 1 de julio de 2026 M | 63 221 | 0 | 5 | $-5 695 855 |
| Ching Jaw | SVP Finance & CFO | 6 de marzo de 2023 A | 87 346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 28 de febrero de 2017 F | 40 323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 22 de septiembre de 2026 M | 153 902 | 0 | 21 | $-4 654 735 |
| Andrew Callos | EVP, Chief Commercial Officer | 31 de agosto de 2026 M | 58 555 | 0 | 25 | $-16 021 293 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 15 de marzo de 2026 A | 107 943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 3 de diciembre de 2024 A | 18 655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 30 de agosto de 2024 A | 33 140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 15 de marzo de 2022 M | 103 408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 7 de marzo de 2022 F | 153 233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 27 de febrero de 2018 A | 32 548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 27 de febrero de 2018 A | 21 520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 31 de agosto de 2017 M | 46 441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 28 de febrero de 2017 A | 29 004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 28 de febrero de 2017 A | 47 255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 28 de febrero de 2011 A | 42 000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 18 de diciembre de 2009 M | 20 043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 29 de febrero de 2008 A | 47 896 | 0 | 0 | $0 |
| Robert E Landry | Consejero | 15 de septiembre de 2026 S | 8 184 | 0 | 2 | $-146 790 |
| Lynne B Parshall | Consejero | 1 de septiembre de 2026 S | 10 784 | 0 | 4 | $-1 357 500 |
| Robert Arthur Harrington | Consejero | 15 de julio de 2026 A | 21 932 | 0 | 1 | $-143 620 |
| James M Daly | Consejero | 15 de julio de 2026 A | 3 390 | 0 | 0 | $0 |
| Edward M. Kaye MD | Consejero | 15 de julio de 2026 A | 10 434 | 0 | 4 | $-2 837 811 |
| Nancy Wysenski | Consejero | 15 de julio de 2026 A | 33 992 | 0 | 0 | $0 |
| Wendell Wierenga | Consejero | 15 de julio de 2026 A | 35 563 | 0 | 3 | $-1 881 925 |
| John T Henderson | Consejero | 15 de julio de 2026 A | 78 360 | 0 | 2 | $-2 078 525 |
| Muna Bhanji | Consejero | 27 de mayo de 2026 A | 26 361 | 0 | 0 | $0 |
| Wendall Wierenga | Consejero | 15 de julio de 2025 A | 32 345 | 0 | 0 | $0 |
| COSTA SANTO J | Consejero | 15 de mayo de 2024 A | 20 600 | 0 | 0 | $0 |
| Sandford D Smith | Consejero | 2 de enero de 2024 A | 18 801 | 0 | 0 | $0 |
| Robert Califf | Consejero | 3 de enero de 2022 A | 6 003 | 0 | 0 | $0 |
| GAGE L PATRICK | Consejero | 8 de noviembre de 2021 M | 28 932 | 0 | 0 | $0 |
| Denise Gilbert | Consejero | 20 de mayo de 2015 J | · | 0 | 0 | $0 |
| Stephen M Dow | Consejero | 2 de enero de 2013 A | 1 421 052 | 0 | 0 | $0 |
| James A Spudich | Consejero | 18 de mayo de 2011 A | 180 600 | 0 | 0 | $0 |
| Grant A Heidrich III | Consejero | 3 de enero de 2011 A | 93 755 | 0 | 0 | $0 |
| Michael Schmertzler | Consejero | 3 de junio de 2010 S | 4 340 923 | 0 | 0 | $0 |
| Mark Mcdade | Consejero | 21 de mayo de 2009 A | · | 0 | 0 | $0 |
| Charles J Homcy | Consejero | 22 de mayo de 2008 A | · | 0 | 0 | $0 |
| William J Rutter | Consejero | 29 de abril de 2004 C | 172 413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | Propietario del 10% | 29 de abril de 2004 C | 1 615 716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | Propietario del 10% | 29 de abril de 2004 C | 771 052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | Propietario del 10% | 29 de abril de 2004 C | 650 000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | Propietario del 10% | 29 de abril de 2004 C | 755 631 | 0 | 0 | $0 |
| Elisabeth Schnieders | · | 28 de febrero de 2017 A | 43 919 | 0 | 0 | $0 |
| James H Sabry | · | 3 de junio de 2010 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | · | 29 de abril de 2004 C | 24 050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | · | 29 de abril de 2004 C | 625 950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | · | 29 de abril de 2004 C | 1 742 951 | 0 | 0 | $0 |
| SEVIN ROSEN VIII AFFILIATES FUND LP | · | 29 de abril de 2004 C | 15 421 | 0 | 0 | $0 |
| SEVIN ROSEN VI AFFILIATES FUND LP | · | 29 de abril de 2004 C | 127 235 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 54 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,51% | 19 346 NS | 31 de julio de 2026 | N-PORT |
| XMMO · Invesco Exchange-Traded Fund Trust | 0,81% | 882 597 SH | 2 de octubre de 2026 | Diario |
| LABU · Direxion Shares ETF Trust | 0,79% | 50 312 NS | 31 de julio de 2026 | N-PORT |
| IBB · iShares Trust | 0,73% | 1 020 305 SH | 11 de septiembre de 2026 | Diario |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,72% | 53 872 NS | 31 de julio de 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,64% | 107 023 NS | 31 de julio de 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,64% | 102 933 SH | 19 de agosto de 2026 | Diario |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,61% | 9 831 SH | 2 de octubre de 2026 | Diario |
| IQSM · New York Life Investments ETF Trust | 0,35% | 14 748 NS | 31 de julio de 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,34% | 761 130 SH | 19 de agosto de 2026 | Diario |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 72 343 SH | 19 de agosto de 2026 | Diario |
| RSSL · Global X Funds | 0,33% | 63 327 NS | 31 de julio de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,32% | 1 797 986 SH | 19 de agosto de 2026 | Diario |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,32% | 219 413 SH | 19 de agosto de 2026 | Diario |
| IWM · iShares Trust | 0,32% | 3 378 753 SH | 11 de septiembre de 2026 | Diario |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,31% | 53 623 SH | 19 de agosto de 2026 | Diario |
| ISCG · iShares Trust | 0,30% | 39 366 SH | 11 de septiembre de 2026 | Diario |
| PTMC · Pacer Funds Trust | 0,29% | 14 892 NS | 31 de julio de 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,27% | 48 364 NS | 31 de julio de 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,24% | 20 179 NS | 31 de julio de 2026 | N-PORT |
| ESML · iShares Trust | 0,23% | 88 671 SH | 11 de septiembre de 2026 | Diario |
| MIDU · Direxion Shares ETF Trust | 0,22% | 1 994 NS | 31 de julio de 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,22% | 687 NS | 31 de julio de 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,22% | 16 176 NS | 31 de julio de 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,21% | 54 306 NS | 31 de julio de 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0,20% | 15 469 NS | 31 de julio de 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,19% | 3 254 NS | 31 de julio de 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,17% | 40 586 SH | 19 de agosto de 2026 | Diario |
| VB · VANGUARD INDEX FUNDS | 0,14% | 3 113 794 SH | 19 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,14% | 333 056 SH | 19 de agosto de 2026 | Diario |
| VXF · VANGUARD INDEX FUNDS | 0,13% | 1 557 779 SH | 19 de agosto de 2026 | Diario |
| FHLC · FIDELITY COVINGTON TRUST | 0,12% | 52 671 NS | 31 de julio de 2026 | N-PORT |
| ESSC · Strategy Shares | 0,10% | 466 NS | 31 de julio de 2026 | N-PORT |
| WSML · iShares Trust | 0,09% | 7 841 SH | 11 de septiembre de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,07% | 15 233 SH | 19 de agosto de 2026 | Diario |
| IWO · iShares Trust | 0,07% | 133 196 SH | 11 de septiembre de 2026 | Diario |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,07% | 27 265 SH | 2 de octubre de 2026 | Diario |
| TILT · FlexShares Trust | 0,02% | 5 740 NS | 31 de julio de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 4 315 260 SH | 19 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 10 880 SH | 19 de agosto de 2026 | Diario |
| ESGV · VANGUARD WORLD FUND | 0,02% | 29 174 SH | 19 de agosto de 2026 | Diario |
| IUSG · iShares Trust | 0,01% | 64 511 SH | 11 de septiembre de 2026 | Diario |
| IUSV · iShares Trust | 0,01% | 53 197 SH | 11 de septiembre de 2026 | Diario |
| ITOT · iShares Trust | 0,01% | 180 021 SH | 11 de septiembre de 2026 | Diario |
| IWV · iShares Trust | 0,01% | 36 083 SH | 10 de septiembre de 2026 | Diario |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 106 638 SH | 19 de agosto de 2026 | Diario |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,00% | 478 SH | 29 de septiembre de 2026 | Diario |
| IJH · iShares Trust | · | 4 763 860 SH | 11 de septiembre de 2026 | Diario |
| IJK · iShares Trust | · | 425 186 SH | 11 de septiembre de 2026 | Diario |
| IJJ · iShares Trust | · | 318 457 SH | 21 de agosto de 2026 | Diario |
| IWN · iShares Trust | · | 1 107 696 SH | 11 de septiembre de 2026 | Diario |
| XJH · iShares Trust | · | 18 548 SH | 8 de septiembre de 2026 | Diario |
| ISCB · iShares Trust | · | 5 565 SH | 11 de septiembre de 2026 | Diario |
| SMLF · iShares Trust | · | 71 881 SH | 11 de septiembre de 2026 | Diario |
CYTK Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
calificación · 28 analistas
COMPRA
Objetivo mediano
$107.50
+63,9%
6 21,4%
Compra fuerte
19 67,9%
Compra
3 10,7%
Mantener
0 0,0%
Venta
0 0,0%
Venta fuerte
Precio objetivo a 12 meses
20 analistas · 2026-09-29Objetivo medio $109.90 +67,5%
← Por Debajo de Todos los Objetivos
Precio Actual $65.60
Mín$85.00
Media$109.90
Máx$146.00
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | · |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | · |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | · |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | · |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | · |
| PCVX | $6.05B | -8.2 | · | · | -26.6% | · |
| TGTX | $4.63B | 10.8 | 87.3% | 72.6% | 96.7% | · |
| SYRE | $2.56B | 10.1 | -62.0% | · | -26.5% | · |
| PRAX | $7.43B | -21.9 | 249.5% | · | -47.3% | · |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Fuente: SEC 10-Q presentada el Ago 6, 2026